DrugPatentWatch Database Preview
Details for Patent: 6,730,325
Which drugs does patent 6,730,325 protect, and when does it expire?
This patent has one hundred and forty patent family members in thirty-three countries.
Summary for Patent: 6,730,325
Title: | Multiparticulate modified release composition |
Abstract: | The invention relates to a multiparticulate modified release composition that in operation delivers an active ingredient in a pulsed or bimodal manner. The multiparticulate modified release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of active ingredient containing particles and the modified release component comprising a second population of active ingredient containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or a bimodal manner. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition. The plasma profile achieved by the multiparticulate modified release composition is advantageous in reducing patient tolerance to the active ingredient and in increasing patient compliance by reducing dosage frequency. |
Inventor(s): | Devane; John G. (Athlone, IE), Stark; Paul (Athlone, IE), Fanning; Niall M. M. (Athlone, IE) |
Assignee: | Elan Corporation, plc (Dublin, IE) |
Application Number: | 09/850,425 |
Patent Claim Types: see list of patent claims | Composition; Delivery; Formulation; Dosage form; Use; |
Drugs Protected by US Patent 6,730,325
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | FOCALIN XR | dexmethylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021802-001 | May 26, 2005 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION | ➤ Sign Up | ||
Novartis | FOCALIN XR | dexmethylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021802-002 | May 26, 2005 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION | ➤ Sign Up | ||
Novartis | FOCALIN XR | dexmethylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021802-004 | Aug 1, 2006 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION | ➤ Sign Up | ||
Novartis | FOCALIN XR | dexmethylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021802-003 | May 26, 2005 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION | ➤ Sign Up | ||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 6,730,325
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
6,902,742 | Multiparticulate modified release composition | ➤ Sign Up |
7,580,712 | Wireless high-speed data network planning tool | ➤ Sign Up |
8,119,163 | Nanoparticulate and controlled release compositions comprising cefditoren | ➤ Sign Up |
6,228,398 | Multiparticulate modified release composition | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 6,730,325
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 021858 | ➤ Sign Up | |||
Austria | 411011 | ➤ Sign Up | |||
Australia | 1335000 | ➤ Sign Up | |||
Australia | 2004202078 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |